1. Home
  2. LPSN vs AKTX Comparison

LPSN vs AKTX Comparison

Compare LPSN & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LivePerson Inc.

LPSN

LivePerson Inc.

HOLD

Current Price

$1.57

Market Cap

21.6M

Sector

Technology

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$9.51

Market Cap

18.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LPSN
AKTX
Founded
1995
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.6M
18.2M
IPO Year
2000
2014

Fundamental Metrics

Financial Performance
Metric
LPSN
AKTX
Price
$1.57
$9.51
Analyst Decision
Hold
Strong Buy
Analyst Count
1
3
Target Price
N/A
$33.50
AVG Volume (30 Days)
86.3K
91.1K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$249,838,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.12
52 Week High
$7.54
$29.32

Technical Indicators

Market Signals
Indicator
LPSN
AKTX
Relative Strength Index (RSI) 29.33 40.44
Support Level $0.39 $9.20
Resistance Level $2.44 $15.50
Average True Range (ATR) 0.08 1.93
MACD -0.01 -0.36
Stochastic Oscillator 2.53 5.50

Price Performance

Historical Comparison
LPSN
AKTX

About LPSN LivePerson Inc.

LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Companies enterprise-class digital customer conversation platform, is trusted by the brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United States, Asia-Pacific, Latin America, and Europe.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: